Claims for Patent: 6,451,534

Summary for Patent: 6,451,534

Title:	KVLQT1--a long QT syndrome gene
Abstract:	The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
Inventor(s):	Keating; Mark T. (Salt Lake City, UT), Sanguinetti; Michael C. (Salt Lake City, UT), Curran; Mark E. (Encinitas, CA), Landes; Gregory M. (Northboro, MA), Connors; Timothy D. (Hopkinton, MA), Burn; Timothy C. (Hockessin, DE), Splawski; Igor (Salt Lake City, UT)
Assignee:	University of Utah Research Foundation (Salt Lake City, UT) Genzyme Corporation (Framingham, MA)
Application Number:	09/597,732
Patent Claims:	1. An isolated nucleic acid selected from the group consisting of SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ D NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73 and SEQ ID NO:74. 2. A pair of nucleic acid primers wherein said primers are: a) SEQ ID NOs:41 and 42; b) SEQ ID NOs:43 and 44; c) SEQ ID NOs:45 and 46; d) SEQ ID NOs:47 and 48; e) SEQ ID NOs:49 and 50; f) SEQ ID NOs:51 and 52; g) SEQ ID NOs:53 and 54; h) SEQ ID NOs:55 and 56; i) SEQ ID NOs:57 and 58; j) SEQ ID NOs:59 and 60; k) SEQ ID NOs:61 and 62; l) SEQ ID NOs:63 and 64; m) SEQ ID NOs:65 and 66; n) SEQ ID NOs:67 and 68; o) SEQ ID NOs:69 and 70; p) SEQ ID NOs:71 and 72; or q) SEQ ID NOs:73 and 74. 3. An isolated nucleic acid comprising any 15 consecutive nucleotides of SEQ ID NO:1 or its complement wherein SEQ ID NO:1 comprises one or more mutations selected from the group consisting of: an A at base 664, an A at base 1102, a G at base 1106, a C at base 1116, a C at base 1220, a T at base 1258, a deletion of bases 662-664, a C at base 694, an A at base 727, an A at base 731, an A at base 922, a T at base 979, an A at base 1078, a T at base 1097, an A at base 1184, a T at base 1184 and an A at base 1196, and wherein said isolated nucleic acid comprises one or more of said mutations. 4. An isolated nucleic acid comprising any 12 consecutive nucleotides of SEQ ID NO:1 or its complement wherein SEQ ID NO:1 comprises one or more mutations selected from the group consisting of: an A at base 664, an A at base 1102, a G at base 1106, a C at base 1116, a C at base 1220, a T at base 1258, a deletion of bases 662-664, a C at base 694, an A at base 727, an A at base 731, an A at base 922, a T at base 979, an A at base 1078, a T at base 1097, an A at base 1184, a T at base 1184 and an A at base 1196, and wherein said isolated nucleic acid comprises one or more of said mutations. 5. An isolated nucleic acid comprising any 23 consecutive nucleotides of a nucleic acid encoding a Xenopus KVLQT1 polypeptide having the amino acid sequence set forth int SEQ ID NO:113 or its complement. 6. An isolated nucleic acid comprising any 25 consecutive nucleotides of a nucleic acid encoding a Xenopus KVLQT1 polypeptide having the amino acid sequence set forth int SEQ ID NO:113 or its complement. 7. An isolated nucleic acid comprising any 15 consecutive nucleotides of SEQ ID NO:115 or its complement. 8. An isolated nucleic acid comprising any 12 consecutive nucleotides of SEQ ID NO:115 or its complement. 9. An isolated nucleic acid comprising any 15 consecutive nucleotides of SEQ ID NO:115 or its complement wherein SEQ ID NO:115 comprises one or more mutations selected from the group consisting of: an A at base 304, an A at base 742, a G at base 746, a C at base 756, a C at base 860, a T at base 898, a deletion of bases 302-304, a C at base 334, an A at base 367, an A at base 371, an A at base 562, a T at base 619, an A at base 718, a T at base 737, an A at base 824, a T at base 824 and an A at base 836, and wherein said isolated nucleic acid comprises one or more of said mutations. 10. An isolated nucleic acid comprising any 12 consecutive nucleotides of SEQ ID NO:115 or its complement wherein SEQ ID NO:115 comprises one or more mutations selected from the group consisting of: an A at base 304, an A at base 742, a G at base 746, a C at base 756, a C at base 860, a T at base 898, a deletion of bases 302-304, a C at base 334, an A at base 367, an A at base 371, an A at base 562, a T at base 619, an A at base 718, a T at base 737, an A at base 824, a T at base 824 and an A at base 836, and wherein said isolated nucleic acid comprises one or more of said mutations. 11. A method of amplifying an exon of KVLQT1 wherein said method comprises: a) contacting a test sample with a pair of primers, wherein said pair of primers is useful for amplifying an exon of KVLQT1 and each of said pair of primers comprises a nucleotide sequence at an intron/exon boundary; b) conducting an amplification reaction to amplify an exon of KVLQT1. 12. The method of claim 11, wherein said pair of primers are selected from the group consisting of the primer pairs a) SEQ ID NOs:41 and 42; b) SEQ ID NOs:43 and 44; c) SEQ ID NOs:45 and 46; d) SEQ ID NOs:47 and 48; e) SEQ ID NOs:49 and 50; f) SEQ ID NOs:51 and 52; g) SEQ ID NOs:53 and 54; h) SEQ ID NOs:55 and 56; i) SEQ ID NOs:57 and 58; j) SEQ ID NOs:59 and 60; k) SEQ ID NOs:61 and 62; l) SEQ ID NOs:63 and 64; m) SEQ ID NOs:65 and 66; n) SEQ ID NOs:67 and 68; o) SEQ ID NOs:69 and 70; p) SEQ ID NOs:71 and 72; and q) SEQ ID NOs:73 and 74.

Details for Patent 6,451,534

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-12-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-12-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-12-22